Characterizing Pyoderma Gangrenosum Lesion Regression and Remission by IL-36 Receptor Targeting With Spesolimab
Spesolimab, an IL-36 receptor antagonist, is being investigated for the treatment of moderate to severe pyoderma gangrenosum (PG), a rare and debilitating autoimmune skin condition. The study's termination indicates a strategic pivot towards a multicenter national study, which may enhance data robustness and market appeal. The competitive landscape includes existing therapies for PG, but no gold standard treatment currently exists, presenting a significant market opportunity for effective therapies. The asset's collaboration with Boehringer Ingelheim may strengthen its development and commercialization prospects, particularly in expanding indications for IL-36 targeting therapies.
Indication: Pyoderma Gangrenosum
Modality: small molecule
Target: IL-36 Receptor
Sponsor: Icahn School of Medicine at Mount Sinai
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 21, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: IL-36 Receptor
View original source fields
Condition raw: Pyoderma Gangrenosum
Condition normalized: Pyoderma Gangrenosum
Modality raw: small molecule
Modality normalized: small molecule
Target raw: IL-36 Receptor
Target normalized: IL-36 Receptor